Ten of the 17 relevant studies (59%) produced
results significantly favoring SJW over placebo on
the prospectively defined primary efficacy endpoint;
therefore, they were deemed positive. All 10
positive studies were in patients with mild-tomoderate
depression. Of the seven negative studies,
five were in mild or moderately depressed patients
and two were in more severely depressed subjects.
!ree of these studies are better described as
“failed,” including one of the two studies with
subjects with severe symptoms. !is is because
they included an active treatment arm that also did
not separate from placebo, raising questions about
the assay sensitivity of those trials.